Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Europe United Kingdom Health Technology Assessment

England Launches Innovative Medicines Fund

  • News

Executive Summary

The new financing mechanism promises faster access to new treatments, but some industry concerns remain unresolved.

You may also be interested in...



England’s Innovative Medicines Fund: Opportunities & Risks

England’s Innovative Medicines Fund could make the UK a more attractive launch market following Brexit, but companies must also consider the risks of the fund.

England: HTA Body NICE Makes Big RWE Push

England’s health technology appraisal institute, NICE, has published its real-world evidence framework.

England’s Innovative Medicines Fund To Put Spotlight On Rare Disease Treatments

While the much-anticipated Innovative Medicines Fund is likely to benefit rare diseases in particular, other products must gain too.

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
Europe United Kingdom Health Technology Assessment
Latest News

Arnold Ventures: How A Philanthropy Helped Tip The Scales In US Drug Pricing Debate

It’s The Overall Survival, Sponsors! Ovarian Cancer Indications Withdrawn For Three PARP Inhibitors

It’s The Overall Survival, Sponsors! Ovarian Cancer Indications Withdrawn For Three PARP Inhibitors

Cell, Gene Therapy A No Entry Zone? EU Group Seeks Clarification Over China Regs

See All
UsernamePublicRestriction

Register

PS146291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By